Jazz and Lilly cancer drugs cleared for use by NHS
Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.
FDA kicks off review of Roche's Gazyva for wider lupus use
Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.
Italy leads the way on child genetic disease diagnosis
A scheme to hasten the diagnosis of children with genetic disorders is achieving strong results and could be a template for national health systems.
UK Knowledge Quarter welcomes Boehringer Ingelheim AI accele...
Boehringer Ingelheim has announced expansion of its global Computational Innovation footprint with a new centre dedicated to AI & ML in the UK.
Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia
Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions
PHARMAP 2026: From Vendors to Strategic Partners
Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers
6th mRNA‑Based Therapeutics Summit
Advancing mRNA's Therapeutic Potential to Combat All Diseases
Agentic AI is Ready. Most Pharma Organizations Are Not
Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey